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Abstract
Background: Tuberculosis (TB) is an important cause of human suffering and death. Human immunodeficiency virus (HIV),
multi-drug resistant TB (MDR-TB), and extensive drug resistant tuberculosis (XDR-TB) have emerged as threats to TB control.
The association between MDR-TB and HIV infection has not yet been fully investigated. We conducted a systematic review
and meta-analysis to summarize the evidence on the association between HIV infection and MDR-TB.
Methods and Results: Original studies providing Mycobacterium tuberculosis resistance data stratified by HIV status were
identified using MEDLINE and ISI Web of Science. Crude MDR-TB prevalence ratios were calculated and analyzed by type of
TB (primary or acquired), region and study period. Heterogeneity across studies was assessed, and pooled prevalence ratios
were generated if appropriate. No clear association was found between MDR-TB and HIV infection across time and
geographic locations. MDR-TB prevalence ratios in the 32 eligible studies, comparing MDR-TB prevalence by HIV status,
ranged from 0.21 to 41.45. Assessment by geographical region or study period did not reveal noticeable patterns. The
summary prevalence ratios for acquired and primary MDR-TB were 1.17 (95% CI 0.86, 1.6) and 2.72 (95% CI 2.03, 3.66),
respectively. Studies eligible for review were few considering the size of the epidemics. Most studies were not adjusted for
confounders and the heterogeneity across studies precluded the calculation of a meaningful overall summary measure.
Conclusions: We could not demonstrate an overall association between MDR-TB and HIV or acquired MDR-TB and HIV, but
our results suggest that HIV infection is associated with primary MDR-TB. Future well-designed studies and surveillance in all
regions of the world are needed to better clarify the relationship between HIV infection and MDR-TB.
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Introduction
The Human Immunodeficiency Virus (HIV) pandemic is one of
the greatest challenges facing tuberculosis (TB) control. Immune
suppression increases the risk of reactivation of latent TB infection
and rapid progression to active TB disease [1]. TB diagnosis is
more difficult in people living with HIV infection and initiation of
HIV treatment can paradoxically worsen TB by restoring immune
function [2]. The effects of HIV on TB result in a strong
correlation between HIV prevalence and TB incidence rates [3].
Overall, an estimated 8% of new TB cases are attributable to HIV
co-infection [4]. The TB incidence rate and HIV prevalence
among new TB cases is highest in sub-Saharan Africa. The leading
cause of death among HIV infected patients in the developing
world is TB. An estimated 13% of the 1.5 million TB deaths in
2006 were attributed to HIV infection, but in the African region
this proportion has been much higher [3]. The risk of death in co-
infected patients is twice that of HIV–infected individuals without
TB, even when CD4+ cell count and antiretroviral therapy are
taken into account [5].
Multidrug resistant tuberculosis (MDR-TB), defined as Mycobac-
teriumtuberculosis resistant toisoniazidand rifampin,furtherthreatens
TB control because of high treatment failure and death rates, and
complexities in diagnosis and treatment. MDR-TB can be a result
of failure of drug sensitive TB treatment with development of
resistance (acquired MDR-TB) or direct transmission of an MDR
strain (primary MDR). Acquisition can arise from medical error,
poor TB control programs or poor patient adherence to treatment.
A history of prior TB treatment remains the most important risk
factor for MDR-TB [6]. According to the most recent WHO
estimates, 490,000 MDR-TB cases and more than 110,000 MDR-
TB deaths occur annually [4]. The first international MDR-TB
survey demonstrated that MDR-TB was present worldwide, with
‘hot-spots’inRussia,Latviaand theDominicanRepublic[7,8].The
2008 report, which included data until 2007, recorded the highest
rates of MDR-TB ever, observed primary MDR-TB rates greater
than 6% in 14 regions, and warned about extensively drug-resistant
TB (XDR-TB, resistance to rifampin, isoniazid plus resistance to
any fluoroquinolone and any of the second-line anti-TB injectable
drugs) in 45 countries [9].
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surprising that MDR-TB has complicated the picture. HIV and
MDR-TB are an even deadlier combination. More than 50% of
HIV-infected MDR-TB patients in Peru died within two months
of diagnosis [10] and studies with longer follow up observed death
rates ranging from 72 to 89% [11]. A study in the UK estimated
that MDR-TB patients who are immune-compromised are nine
times more likely to die than those not immune-compromised
[12]. In a XDR-TB outbreak in South Africa, 98% of co-infected
patients died with median survival time of 16 days from XDR-TB
diagnosis [13].
Even though the impact of HIV infection on MDR-TB is of
great public health importance, their relationship is not yet fully
understood. HIV infection has been associated with MDR-TB
outbreaks in institutional settings, such as hospitals and prisons
[14,15]. It remains less clear whether HIV infection is also
associated with MDR-TB in community settings. We aimed to
summarize and critically appraise studies in order to quantify the
association between MDR-TB and HIV-infection.
Methods
A systematic review of studies assessing HIV infection as a risk
factor for MDR-TB was carried out using MEDLINE/PubMed,
ISI Web of Science, CINAHL and the Cochrane Library
databases. The keywords ‘‘multi drug resistant tuberculosis’’,
‘‘MDR-TB’’ and ‘‘HIV’’ were used as search terms. Searches were
performed during March 2007 and included articles on human
subject research prior to the search date. We reviewed titles and
abstracts of original studies retrieved by the search, full text and
references of selected articles, and text and references of relevant
review articles published prior to the April 2007 (Figure 1).
Reports on original studies were included, independent of study
design and without restriction of publication date, because of the
low number of eligible studies (Table 1). Articles were included if
they presented results of drug susceptibility to rifampin and
isoniazid of Mycobacterium tuberculosis, stratified by HIV test result,
and when values pertaining to the prevalence odds or prevalence
rate for MDR-TB were extractable from data presented. Studies
on children were not specifically excluded but none of the eligible
published articles presented child data.
For each eligible study, MDR-TB prevalence ratios and
corresponding 95% confidence intervals were calculated from
the reported data. Sample size, use of appropriate statistical
measures to assess the measure of association between MDR-TB
and HIV infection, assessment of potential confounders, and
appraisal of external validity of study results were noted as quality
indicators. Potential confounders included baseline demographic
characteristics such as socioeconomic status, imprisonment and
intravenous drug use.
The association between primary and acquired MDR-TB and
HIV were assessed separately when possible. The standard chi-
square test of homogeneity and associated p-value were calculated,
and pooled prevalence ratios were generated, if appropriate, using
the metan command in the STATA statistical software system
[16]. Prevalence ratios were analyzed by region, study-period and
date of publication.
Results
From PubMed, 738 articles concerned human subjects studies
(Figure 1). ISI/Web of Science yielded 593 studies while the other
databases yielded 30 additional studies. Eligibility criteria were
met by 27 articles. One potentially eligible study published in
Figure 1. Search strategy.
doi:10.1371/journal.pone.0005561.g001
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access could not be gained to the full article or data. References of
the 26 articles and two review articles [18,19] were hand-searched,
yielding 6 additional eligible studies. The resulting 32 studies,
which had study populations varying from 46 to 19,646, were
carried out between 1988 and 2006, and represented 17 countries
Table 1. MDR-TB prevalence by HIV status in 32 studies.
Ref. Country MDR-TB type Study period
Number of
HIV+ patients
MDR-TB in
HIV+ patients
Number of
HIV2 patients
MDR-TB in
HIV2 patients
[20] Thailand Any 2000 192 5.2% 685 0.4%
[21] Thailand Primary 2001 377 8.5% 474 4.4%
Acquired 49 40.8% 85 32.9%
[22] India Primary 00–’04 30 10.0% 40 2.5%
[23] Vietnam Primary 98–’00 40 7.5% 1393 3.7%
Acquired 11 9.1% 390 25.9%
[24] Cote d’Ivoire Any 1989 17 0.0% 29 3.4%
[25] Tanzania Primary 91–’93 275 0.4% 816 0.4%
Acquired 21 0.0% 52 3.8%
[26] South Africa Any 91–’94 42 2.4% 253 11.5%
[27] South Africa Primary 94–’96 93 3.2% 115 2.6%
[28] South Africa Any 1995 207 5.3% 215 6.5%
[29] Botswana Any 95–’96 117 0.9% 123 0.8%
[30] Mozambique Any 98–’99 179 2.2% 530 3.2%
[31] Italy Any 90–’92 34 2.9% 373 5.9%
[32] Portugal Any 95–’98 29 44.8% 113 17.7%
[33] Spain Primary 88–’92 184 0.5% 317 0.6%
[34] Spain Any ’96–’00 59 0.0% 926 0.1%
[35] France Primary ’92–’94 893 1.2% 5864 0.3%
Acquired 107 11.2% 868 6.6%
[36] France Primary 95–’97 246 0.0% 2007* 0.4%
Acquired 28 7.1% 226* 3.5%
[37] United Kingdom Any 93–’99 910 4.6% 24307* 1.1%
[38] United Kingdom Primary 93–’94, ’98–’00 274 3.6% 7936* 1.0%
Acquired 19 21.1% 611* 8.2%
[39] United Kingdom Any 94–’96 460 6.1% 9682* 1.3%
[40] Brazil Any 95–’97 142 13.4% 151 0.0%
[41] Brazil Any 96–’00 16 6.3% 76 6.6%
[42] Brazil Any 00–’02 72 2.8% 292 6.2%
[43] Peru All ’99–’00 81 43.2% 965* 3.9%
[44] Haiti Primary ’00–’02 115 9.6% 166 3.0%
Acquired 16 0.0% 33 30.3%
[45] New York City Primary ’91 82 19.5% 145* 2.1%
[46] New York City Primary ’94 45 16.0% 104* 1.0%
[47] New Jersey Any ’91–’95 556 4.9% 413 1.2%
[48] United States Any ’92–’94
New York City 252 19.4% 69 5.8%
non-NYC 179 2.8% 473 1.4%
[49] United States Any 93–’96
US born 5375 6.4% 3929 1.4%
foreign born 957 4.7% 1867 3.0%
[50] United States Any 93–’94 4029 4.8% 21679** 0.6%
[51] Texas Any ’87–’96 2221 1.1% 15204** 1.4%
*includes patients with unknown HIV status.
**all patients have unknown HIV status.
doi:10.1371/journal.pone.0005561.t001
HIV and MDR-TB
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5561in 5 regions: South/Southeast Asia, Sub-Saharan Africa, Western
Europe, Latin America, and North America (Table 1). Crude
prevalence ratios and corresponding 95% confidence intervals are
presented by region in Figure 2.
South/Southeast Asia
In Bangkok, Thailand, an increased rate (RR 11.9, 95% CI 4.3,
33) of MDR-TB was found among 192 HIV co-infected patients,
compared to 685 HIV-negative patients [20]. Groups were
comparable for TB risk factors but only a small number of
eligible patients were tested for HIV infection and TB drug
susceptibility, which could have introduced selection bias.
A study in Northern Thailand found an association between
HIV infection and primary MDR-TB (OR 2.0, 95% CI: 1.1, 3.5),
but not acquired MDR-TB (OR 1.40, 95% CI: 0.68, 2.91) [21].
There was no baseline comparison of risk factors among the 426
HIV-positive and 559 HIV-negative patients.
A small (n=70) Indian study observed similar rates of MDR-TB
in HIV co-infected (10%) and HIV-negative patients (2.5%) [22].
A study from Vietnam showed no difference in primary MDR-
TB prevalence rate among 40 HIV co-infected (7.5%) and 1393
HIV-negative patients (3.7%), even after adjustment for age, sex
and treatment history. The rate of acquired MDR-TB was lower
in 11 HIV co-infected (9.1%) than in 390 HIV-negative patients
(25.9%) [23].
Sub-Saharan Africa
Braun et al. undertook one of the first studies of antituberculosis
drug resistance and HIV in sub-Saharan Africa [24]. In this small
(n=46) study from Cote d’Ivoire, MDR-TB rates among HIV co-
infected (0%) and HIV negative (3.4%) patients were similar.
A large survey in Tanzania studied one-sixth of incident TB
cases from each district over a three year period [25]. Among 1091
new TB cases, similar MDR-TB prevalence rates were found by
HIV status (0.36% for co-infected and 0.37% for HIV-negative).
Rates of acquired MDR-TB were 0% among 21 HIV co-infected
and 3.8% among 52 HIV-negative patients. While no statistical
testing was presented, the authors did provide limited baseline
characteristics by HIV status.
Three studies in South Africa also found no association between
HIV infection and MDR-TB. In a retrospective study in Durban,
2.4% of 42 HIV co-infected and 11.5% of 253 HIV-negative
patients had MDR-TB [26]. A prospective study of hospitalized
TB patients in Cape Town found a MDR-TB prevalence of 3.2%
in 93 HIV co-infected patients, compared to 2.6% in 115 HIV-
negative patients [27]. In goldminers, the MDR-TB rate was 5.3%
among 207 HIV co-infected and 6.5% among 215 HIV-negative
miners [28]. Only limited baseline characteristics and no statistical
tests results were presented by these three studies.
A national survey using random sampling in Botswana also
found similar MDR-TB prevalence rates among 107 HIV co-
infected (0.9%) and 119 HIV-negative patients (0.8%) [29]. No
information was provided on baseline characteristics by HIV
infection status.
A study in Mozambique of 179 HIV co-infected and 530 HIV-
negative TB patients, found an odds ratio of 0.7 (95% CI: 0.2, 2.2)
for the association between MDR-TB and HIV infection. Baseline
characteristics showed differences by HIV status in level of
education, history of sexually transmitted diseases, and history of
TB treatment [30].
Europe
A study of hospitalized TB patients in Rome, Italy found that
2.9% of 34 HIV co-infected patients and 5.9% of 373 patients
without documented HIV status had MDR-TB (OR 0.5, 95% CI:
0.1–3.2) [31]. Patient characteristics were not compared by HIV
status.
A Portuguese study found a higher MDR-TB rate among 29
HIV co-infected patients (44.8%) compared to 17.7% among 113
HIV-negative patients [32].
Two studies from Spain addressed the issue of MDR-TB and
HIV infection. In Barcelona, the primary MDR-TB rate was
similar among 184 HIV co-infected (0.5%) and 317 HIV-negative
patients (0.6%). Statistical testing was not provided and potential
confounders were not assessed [33]. In the Spanish Castilla-Leon
region, equally low rates of MDR-TB were observed among HIV
co-infected (0%) and HIV-negative patients (0.1%) (OR 0.19, 95%
CI: 0, 4.8) [34]. Comparison of baseline characteristics by HIV
status was not addressed.
A large survey (n=13,344) conducted in the early 1990’s in
France, representing 80% of French public hospital beds, observed
an association between primary MDR-TB and HIV (OR of 3.3;
95% CI: 1.5, 7.3), but not for acquired MDR-TB (OR 1.0; 95%
CI 0.5, 2.0) when adjusted for sex, age, and region of origin [35].
A smaller (n=2998) French survey found no statistically significant
association between primary or acquired MDR-TB and HIV
infection [36].
Three surveillance studies with some overlapping data from the
United Kingdom have been published. A survey of 910 HIV co-
infected patients and 24,307 HIV-negative patients found an odds
ratio of 4.6 (95% CI 3.3, 6.2) for MDR-TB by HIV status [37].
Another study found an association between HIV infection and
primary MDR-TB (OR 3.6, 95% CI 1.8, 7.0), but no association
between acquired MDR-TB and HIV infection (OR 2.2; 95% CI
0.7, 6.9) [38]. A third study suggested higher MDR-TB rates
among HIV-infected patients (6.1% vs. 1.3%) [39]. None of these
three studies presented patient characteristics by HIV status.
Latin America
Three Brazilian studies assessed MDR-TB rates by HIV status.
One study suggested a higher rate (13.4% vs. 0%) of MDR-TB
(13.4%) among 142 HIV co-infected compared to 151 HIV-
negative patients [40]. Gentoype patterns suggested that most
MDR-TB cases were recently transmitted infections. Baseline
characteristics were not addressed by HIV status. A small (n=92)
study found no relationship between MDR-TB rates by HIV
status (6.3% among HIV co-infected and 6.6% among HIV-
negative patients) [41]. The two groups differed regarding
proportion male, injection drug use, and male homosexual
relations. A subsequent cross sectional study also found no
relationship between MDR-TB and HIV infection, with 2.8% of
72 co-infected patients and 6.2% of 292 HIV-negative patients
having MDR-TB [42].
A study in Peru found an association between HIV infection
and MDR-TB, with 43.2% of 81 HIV co-infected and 3.9% of
965 HIV-negative patients having a diagnosis of MDR-TB [43].
Important differences between groups included socio-economic
status, TB treatment history, TB exposure, and use of medical
services in the year preceding active TB. Important to note is that
HIV co-infected patients were recruited from hospitals, whereas
HIV negative controls were recruited from ambulatory clinics.
In Haiti, a study found an increased risk for primary MDR-TB
among the 115 patients with HIV co-infection (RR 3.2, 95%CI
1.1, 8.9), but no increased risk for acquired MDR-TB. Prevalence
of acquired MDR-TB was actually higher among HIV-negative
patients [44]. Baseline characteristics were not compared by HIV
status.
HIV and MDR-TB
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5561Figure 2. Forest plot of MDR-TB prevalence ratios by HIV status and corresponding 95% confidence intervals by geographical
region
*.
*Clark O; Djulbegovic B. Forest plots in excel software (Data sheet). 2001. Available at www.evidencias.com.
doi:10.1371/journal.pone.0005561.g002
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In 1993, HIV infection was found to be highly correlated with
MDR-TB in New York City, with 19.5% of HIV co-infected
patients diagnosed with MDR-TB compared to 2.1% of those
without documented acquired immune deficiency syndrome
(P,0.001) [45]. There was no assessment of confounding. A
smaller survey from New York in 1994 also showed an association
between MDR-TB and HIV infection (OR 61.7) [46]. Similarly,
in nearby New Jersey, HIV co-infected patients were at higher risk
of MDR-TB (OR 3.6, 95% CI: 1.5, 8.8) [47]. Factors such as
previous TB, homelessness, and injection drug use were examined,
but not stratified by HIV status.
Another study observed an increased rate of MDR-TB among
HIV co-infected patients in New York (19.4% among 252 HIV co-
infected vs. 5.8% among 69 HIV-negative), but not among
patients residing outside New York City (2.8% among 179 HIV
co-infected vs. 1.4% among 473 HIV-negative) [48]. There was no
comparison of baseline characteristics by HIV status. Analysis of
nationwide TB surveillance data, including a subset of the patients
reported in Gordin et al, showed differences in MDR-TB rates by
HIV status for both US-born (6.4% among 5375 HIV co-infected
vs. 1.4% among 3929 HIV-negative) and foreign-born patients
(4.7% among 957 HIV co-infected vs. 3.0% among 1867 HIV-
negative) [49]. A multivariate model that included age, TB history,
country of birth, residence in New York City, and race/ethnicity,
found HIV infection to be a risk factor for MDR-TB, with rates of
4.8% among 4029 HIV co-infected and 0.6% of 21679 with
unknown HIV status [50]. In some areas of the United States with
low levels of MDR-TB, differences in MDR-TB by HIV status
were not found. A study in Texas found a relative risk for MDR-
TB by HIV status of 0.78 [95% CI: 0.50, 1.21] [51].
Summary Prevalence Ratio
The MDR-TB prevalence ratio in individual studies ranged
from 0.21 to 41.45 and varied widely between studies, between
regions and within regions (Figure 2). The HIV prevalence also
varied widely between studies (range 3 to 57%), between regions
(mean 12% to 33%) and within regions. There was no overall
correlation between HIV prevalence and MDR-TB prevalence
ratio (r=0.209) (Figure 3).
The heterogeneity across studies did not allow for the
calculation of one summary prevalence ratio for the relationship
between MDR-TB and HIV infection, despite accounting for
region and study period. The pooled prevalence ratio for acquired
MDR-TB and HIV (8 studies) was 1.17 (95% CI 0.86, 1.6, p-value
for heterogeneity=0.188), the pooled prevalence ratio for primary
MDR-TB and HIV (12 studies) was 2.72 (95% CI 2.03, 3.66, p-
value for heterogeneity=0.356) (Figure 4).
Discussion
While most studies in North America showed an association
between HIV infection and MDR-TB, not a single study from
Africa demonstrated such association, and results from other
regions were conflicting. Individual studies varied widely in study
design and sample size, and results were rarely adjusted for
Figure 3. MDR-TB Prevalence ratio by HIV prevalence among study participants and by region
*.
*One outlier from the Latin American
region (HIV Prevalence: 0.20, Prevalence Ratio: 45) is not presented.
doi:10.1371/journal.pone.0005561.g003
HIV and MDR-TB
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5561potential confounding. These limitations and the observed
heterogeneity precluded a general conclusion regarding the overall
association between HIV infection and MDR-TB. When stratified
by type of MDR-TB, the analysis suggests that primary, but not
acquired, MDR-TB is associated with HIV infection.
Several biological mechanisms linking drug resistant TB to HIV
infection have been suggested [52]. Drug malabsorption in HIV-
infected patients, especially rifampin and ethambutol, can lead to
drug resistance and has been shown to lead to treatment failure
[53]. Drug resistant strains may be less virulent and preferentially
lead to disease progression in immune compromised patients, as
opposed to immune-competent individuals. Data supporting this
hypothesis has not yet been observed in humans.
However, the association between HIV infection and MDR-TB
could be confounded by other factors. First, an observed
association could be confounded by time window. HIV-negative
patients are likely to reactivate a latent infection from decades ago,
whereas HIV infected patients, in whom disease progresses
rapidly, are likely to reactivate an infection acquired more recently
following community or institutional transmission. With increasing
prevalence of drug resistance globally [54], a higher percentage of
recent infections are likely to be multi-drug resistant, resulting in
higher rates of MDR-TB in HIV-positive individuals. The
significant associations between HIV infection and primary
MDR-TB, but not between acquired MDR-TB and HIV
infection, support this [21,35,38,44]. Similarly, the observed
association between XDR-TB and HIV infection may be a result
of the recent evolution of XDR-TB [13].
Second, the association between HIV infection and MDR-TB
may be confounded by shared risk factors such as injection drug
use, imprisonment, socioeconomic status, alcohol use and
hospitalization. Intravenous drug use is a risk factor for HIV
infection and non-adherence to treatment, the latter promoting
development of drug resistance [55]. HIV-infected patients and
MDR-TB patients are more likely to be hospitalized compared to
those who are HIV negative or suffer from drug sensitive TB.
HIV-infected patients may thus be more likely to be exposed to
patients with drug resistant isolates, and thus be infected or re-
infected with a resistant isolate. The associations between MDR-
TB and HIV infection observed in many North American studies,
which included in part patients involved in institutional outbreaks
in New York City, support this possibility.
Several limitations restrict the interpretation of our findings.
Publication bias, an important concern in meta-analysis of
randomized control trials, may have been present but was most
likely not substantial as many studies were not designed to assess
Figure 4. Forest plots of acquired (A) and primary (B) MDR-TB prevalence ratios by HIV status and corresponding 95% confidence
intervals
*.
*Clark O; Djulbegovic B. Forest plots in excel software (Data sheet). 2001. Available at www.evidencias.com.
doi:10.1371/journal.pone.0005561.g004
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studied included in this review observed no relationship between
MDR-TB and HIV infection. The quality of many studies was
poor due to small sample size and lack of adjustment for possible
confounders in all but 7 studies. As the primary aim of many
studies was not to assess the association between HIV infection
and MDR-TB, studies could have suffered from misclassification
bias due to inclusion of patients with unknown HIV status, and
participation bias when HIV infected individuals were more likely
to be tested for drug resistance [18]. Level of immunosuppression
(CD4 count) was not presented, and most studies were performed
prior to the introduction of highly active antiretroviral therapy.
Data from MDR-TB hot-spots, such as Russia, Eastern Europe,
and China, were not available. One potentially eligible study from
the Samara region in Russia was excluded due lack of access to the
data. Inclusion of this article would most likely not have changed
our conclusion as the abstract states that ‘‘HIV infection is
unassociated with resistance’’. Finally, studies not published in
peer reviewed journals were excluded. Two reports deserve special
attention. A large South African survey did not find a difference in
MDR-TB rates by HIV status (p=0.575) [56]. In the 2008 report
on antituberculosis drug resistance in the world [9], only 7 of 81
countries reported data in drug resistance stratified by HIV status,
and only Latvia and one oblast in Ukraine (Donetsk Oblast)
reported large enough numbers to examine the association
between HIV infection and MDR-TB. MDR-TB was associated
with HIV infection in both Latvia (OR 2.1; 95% CI 1.4, 3.0) and
Ukraine (OR 1.5, 95% CI 1.1, 2.0), but HIV negative and HIV
unknown were not distinguished in Latvia. In Donetsk Oblast,
HIV infection was found to be an independent predictor for
MDR-TB, in addition to history of previous TB treatment and
history of imprisonment [57].
We opted not to present a pooled prevalence ratio for the
overall association between HIV infection and MDR-TB because
of the high degree of heterogeneity among studies. To provide the
least biased estimate of the association between HIV infection and
MDR-TB, future prospective studies will need to be sufficiently
powered and will need to measure HIV status, drug resistance,
history of TB treatment, and potential confounders in all eligible
patients with TB.
While HIV infection and tuberculosis are intimately linked,
there is currently no evidence supporting an association between
MDR-TB and HIV outside of institutional outbreaks. Neverthe-
less, the devastating consequences of HIV and MDR-TB co-
infection and the geographic overlap of these two epidemics
demand urgent attention [18,19]. The high case fatality rates of
MDR and XDR-TB in HIV co-infected patients could have
devastating and demoralizing effects on health care workers and
communities. Concomitant MDR-TB and antiretroviral treatment
requires adherence to 6 to 10 daily medications for more than one
year, and is characterized by high levels of toxicity and drug-drug
interactions, leading to increased complexity of patient manage-
ment. Limited infection control, lack of access to MDR-TB
diagnostics, and poor MDR-TB treatment capacity in resource
poor settings may lead to hospital outbreaks, similar to what had
been observed in New York almost two decades ago [45], and in
South Africa more recently [13].
Intervention, as outlined by the WHO Stop TB Strategy, is
needed to avert a global catastrophe of a dual HIV and MDR-TB
epidemic. Basic TB control needs to be strengthened to achieve
high cure rates and prevent ongoing generation of MDR-TB.
Laboratory capacity for prompt diagnosis of drug resistance,
preferably using rapid diagnostic techniques such as the
GenoType MTBDRplus [58], needs to be built. Capacity for
concomitant MDR-TB and antiretroviral treatment needs to be
scaled up, and collaborations between HIV and TB control
programs need to be strengthened. Infection control measures
need to become a key element of global TB control.
In addition, gaining a better understanding of how HIV
infection impacts the epidemiology of drug resistant TB will be
critical. The public health and medical community should not
have to rely on small, isolated surveys for two of the largest threats
to TB control. Surveillance of MDR-TB and XDR-TB among
HIV positive and negative patients should be an essential part of
global efforts to combat TB and HIV. Universal access to
diagnosis and treatment of HIV and drug resistant TB should be
the ultimate goal. To achieve this, a united front will be needed to
help avert ‘‘the perfect storm’’ [19] of a massive MDR-TB/HIV
co-epidemic, which may turn out to be greater than the sum of its
components.
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